Company Analysis Cellectar Biosciences, Inc.
1. Summary
Advantages
- Price (4.04 $) is less than fair price (8.03 $)
Disadvantages
- Dividends (0%) are below the sector average (0.55%).
- The stock's return over the last year (-54.71%) is lower than the sector average (-5.16%).
- Current debt level 1.94% has increased over 5 years from 0.72%.
- The company's current efficiency (ROE=-689.12%) is lower than the sector average (ROE=104.34%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Cellectar Biosciences, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -5.5% | -16.5% | -0.1% |
| 90 days | 25.1% | -6.6% | 1.2% |
| 1 year | -54.7% | -5.2% | 18% |
CLRB vs Sector: Cellectar Biosciences, Inc. has significantly underperformed the "Healthcare" sector by -49.55% over the past year.
CLRB vs Market: Cellectar Biosciences, Inc. has significantly underperformed the market by -72.67% over the past year.
Stable price: CLRB is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CLRB with weekly volatility of -1.05% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (4.04 $) is lower than the fair price (8.03 $).
Price significantly below the fair price: The current price (4.04 $) is 98.8% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-3.62) is lower than that of the sector as a whole (35.84).
P/E vs Market: The company's P/E (-3.62) is higher than that of the market as a whole (-99.49).
5.3. P/BV
P/BV vs Sector: The company's P/BV (22.76) is lower than that of the sector as a whole (254.49).
P/BV vs Market: The company's P/BV (22.76) is lower than that of the market as a whole (71.88).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (127.81).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (113.77).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-6.84) is higher than that of the sector as a whole (-27.35).
EV/Ebitda vs Market: The company's EV/Ebitda (-6.84) is higher than that of the market as a whole (-78.41).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 17.15% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (17.15%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-1802.65%).
6.4. ROE
ROE vs Sector: The company's ROE (-689.12%) is lower than that of the sector as a whole (104.34%).
ROE vs Market: The company's ROE (-689.12%) is lower than that of the market as a whole (-6.24%).
6.6. ROA
ROA vs Sector: The company's ROA (-237.45%) is lower than that of the sector as a whole (-2.2%).
ROA vs Market: The company's ROA (-237.45%) is lower than that of the market as a whole (38.46%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.59%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.55%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
